Dostarlimab monotherapy produced a 27% response rate in PD-L1-positive recurrent/metastatic head and neck squamous cell carcinoma
Commentary|Articles|June 11, 2026
Head and Neck Oncologists Highlight Practice-Informing Research From ASCO 2026
Author(s)Ashling Wahner
Fact checked by: Chris Ryan, Tracy Ann Politowicz
Experts highlight the most interesting and potentially paradigm-shifting head and neck cancer data to come out of the 2026 ASCO Annual Meeting.
Advertisement
Advertisement
During the
Related to this article
Durable outcomes were reported standard-dose tivozanib monotherapy in second- and third-line metastatic RCC.
Top experts discuss the most important takeaways and data to come out of this year’s ASCO Annual Meeting in ovarian and endometrial cancer.
Low PD-L1 expression and node-negative status identified oral cancer patients most likely to benefit from neoadjuvant leukocyte interleukin injection.
Top experts discuss the most important takeaways and data to come out of this year’s ASCO Annual Meeting in non–small cell lung cancer.
Darlifarnib plus cabozantinib showed durable responses and manageable safety in cabozantinib-naive advanced clear cell RCC.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
A post-hoc analysis of LITESPARK-005 found that higher baseline and improved on-treatment QOL scores tracked with lower risk of disease progression and death.
Advertisement
Advertisement